Efficacy of Docetaxel vs. Paclitaxel in Lung Cancer with Mutation of P53 Gene

Abstract

In this research paper, the main emphasis has been given on the efficacy of docetaxel vs. paclitaxel in lung cancer with mutation of P53 gene. The research from the in-depth analysis of information has identified Docetaxel as an effective source to treat lung cancer which is continuously infecting and attacking people belonging to different walks of life. For the literature search, several research articles have been reviewed and from the review of the research and peer reviewed articles the effects of Docetaxel and Paclitaxel has been identified in the therapy of lungs cancer whereas, the effect of Docetaxel and Paclitaxel has also been highlighted with the P53 gene mutation. Docetaxel early use in the therapeutic arsenal is tempting, especially with the results that can be achieved with Paclitaxel. Furthermore, in this research paper, role of P53 has also been identified and it has been observed that P53gene occupies a very special order function in cell production, as scientists have been describing it in most of the research works. At the end of the paper, conclusion has been provided followed by recommendations.

Table of Content

Abstracti

Introduction1

Scholarly Review2

Introductory Review of the Studied Researches2

Discussion5

Pathophisiologic Information about Lung Cancer5

The Role of P53 Gene in Lung Cancer7

The Effect of Docetaxel and Paclitaxel Therapy In Lung Cancer10

Effect of Docetaxel and Paclitaxel Therapy In Lung Cancer with P53 Gene13

Recommendations for Future Research15

Conclusion16

References18

Efficacy of Docetaxel vs. Paclitaxel in Lung Cancer with Mutation of P53 Gene

Introduction

This research paper aims to find out the effectiveness of Docetaxel in the treatment of lungs cancer along with the mutation of P53 gene. Meta-analyzes of clinical trials in lung cancer cells indicated that chemotherapy increases the survival and improves quality of life. The current provision of new anticancer agents with innovative mechanisms of action, can hope to improve outcomes and survival. Docetaxel is a taxoid derived semi-synthetic precursor 10-deacetyl baccatin III. Its mechanism of action is to promote microtubule assembly and inhibit the de-polymerization of tubulin that stabilizes microtubules (John F. Deeken, et.al, 2012). Pre-clinical studies have shown that Docetaxel did not cross-resistant with platinum salts. For the investigation of efficacy of Docetaxel in comparison with Paclitaxel, several research papers have been studied. However, this paper will also be highlighting the information about lungs cancer and the function of P53 gene in lungs cancer.

From the review of the research and peer reviewed articles the effects of Docetaxel and Paclitaxel has been identified in the therapy of lungs cancer whereas, the effect of Docetaxel and Paclitaxel has also been highlighted with the p53 gene mutation ( Pepperkok, R., Bre, M.H, 1990). Docetaxel is a synthetic taxoid which is currently used in the treatment of metastatic breast cancer. Its early use in the therapeutic arsenal is tempting, especially with the results that can be achieved with Paclitaxel (Wei-Yu Liao, et.al, 2012). However, in past more than 30 years has managed the 5-year survival rate in patients with metastatic (Non-small cell lungs cancer) NSCLC ...